WO2012079878A3 - Peptides se liant au hla dérivés de molécules antigéniques associées à la prostate et procédés d'utilisation associés - Google Patents

Peptides se liant au hla dérivés de molécules antigéniques associées à la prostate et procédés d'utilisation associés Download PDF

Info

Publication number
WO2012079878A3
WO2012079878A3 PCT/EP2011/070024 EP2011070024W WO2012079878A3 WO 2012079878 A3 WO2012079878 A3 WO 2012079878A3 EP 2011070024 W EP2011070024 W EP 2011070024W WO 2012079878 A3 WO2012079878 A3 WO 2012079878A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
prostate
hla
binding peptides
peptides derived
Prior art date
Application number
PCT/EP2011/070024
Other languages
English (en)
Other versions
WO2012079878A2 (fr
Inventor
Toni Weinschenk
Peter Lewandrowski
Hans-Georg Rammensee
Stefan Stevanovic
Cécile GOUTTEFANGEAS
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/069675 external-priority patent/WO2011073215A2/fr
Priority to CN201180059274.2A priority Critical patent/CN103547283A/zh
Priority to US13/993,291 priority patent/US9023804B2/en
Priority to EP11782613.1A priority patent/EP2651434A2/fr
Priority to SG2013045737A priority patent/SG191154A1/en
Priority to NZ60991611A priority patent/NZ609916A/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Priority to MX2013006758A priority patent/MX2013006758A/es
Priority to JP2013543601A priority patent/JP6032853B2/ja
Priority to AU2011344652A priority patent/AU2011344652B2/en
Priority to EA201300693A priority patent/EA201300693A1/ru
Priority to KR1020137018147A priority patent/KR20130126671A/ko
Priority to CA2821582A priority patent/CA2821582A1/fr
Publication of WO2012079878A2 publication Critical patent/WO2012079878A2/fr
Publication of WO2012079878A3 publication Critical patent/WO2012079878A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464495—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des procédés et des compositions de traitement immmunothérapeutique du cancer de la prostate. La présente invention concerne plus spécifiquement des procédés de traitement de patients atteints du cancer de la prostate qui comprennent l'administration de compositions comprenant des peptides se liant au HLA dérivés de molécules antigéniques associées à la prostate, avec ou sans adjuvants immunologiques.
PCT/EP2011/070024 2004-08-19 2011-11-14 Peptides se liant au hla dérivés de molécules antigéniques associées à la prostate et procédés d'utilisation associés WO2012079878A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2821582A CA2821582A1 (fr) 2010-12-14 2011-11-14 Peptides se liant au hla derives de molecules antigeniques associees a la prostate et procedes d'utilisation associes
JP2013543601A JP6032853B2 (ja) 2010-12-14 2011-11-14 前立腺関連抗原分子由来ｈｌａ結合ペプチドおよびその使用方法
EP11782613.1A EP2651434A2 (fr) 2010-12-14 2011-11-14 Peptides se liant au hla dérivés de molécules antigéniques associées à la prostate et procédés d'utilisation associés
SG2013045737A SG191154A1 (en) 2010-12-14 2011-11-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
NZ60991611A NZ609916A (en) 2010-12-14 2011-11-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
CN201180059274.2A CN103547283A (zh) 2010-12-14 2011-11-14 前列腺相关抗原分子来源的人类白细胞抗原结合肽及其使用方法
MX2013006758A MX2013006758A (es) 2010-12-14 2011-11-14 Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.
US13/993,291 US9023804B2 (en) 2004-08-19 2011-11-14 HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
AU2011344652A AU2011344652B2 (en) 2010-12-14 2011-11-14 HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
EA201300693A EA201300693A1 (ru) 2010-12-14 2011-11-14 Образованные из молекул антигенов, ассоциированных с предстательной железой, пептиды, связывающиеся с молекулами hla, и способы их применения
KR1020137018147A KR20130126671A (ko) 2010-12-14 2011-11-14 전립선 관련 항원 분자로부터 유래된 hla 결합 펩티드 및 이의 사용방법

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP2010/069675 2010-12-14
PCT/EP2010/069675 WO2011073215A2 (fr) 2009-12-14 2010-12-14 Peptides se liant aux hla, dérivés de molécules antigéniques associées à la prostate, et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
WO2012079878A2 WO2012079878A2 (fr) 2012-06-21
WO2012079878A3 true WO2012079878A3 (fr) 2012-08-09

Family

ID=44983532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/070024 WO2012079878A2 (fr) 2004-08-19 2011-11-14 Peptides se liant au hla dérivés de molécules antigéniques associées à la prostate et procédés d'utilisation associés

Country Status (9)

Country Link
JP (1) JP6032853B2 (fr)
KR (1) KR20130126671A (fr)
CN (1) CN103547283A (fr)
AU (1) AU2011344652B2 (fr)
CA (1) CA2821582A1 (fr)
MX (1) MX2013006758A (fr)
NZ (1) NZ609916A (fr)
SG (1) SG191154A1 (fr)
WO (1) WO2012079878A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013012432A1 (de) * 2013-07-29 2015-01-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Immuntherapie von Prostatakrebs
MX2016013559A (es) * 2014-04-16 2017-04-27 Biocon Ltd Formulaciones de proteina estables que comprenden un exceso molar de sorbitol.
US10639329B2 (en) * 2015-06-12 2020-05-05 Lentigen Technology, Inc. Method to treat cancer with engineered T-cells
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
EP4317432A3 (fr) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH Récepteurs de lymphocytes t à appariement amélioré
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
SI3580561T1 (sl) * 2017-02-12 2024-04-30 Biontech Us Inc. Metode, osnovane na hla, in njihove sestave ter uporabe
KR102215578B1 (ko) * 2019-03-28 2021-02-15 한국과학기술연구원 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045728A2 (fr) * 1999-12-21 2001-06-28 Epimmune Inc. Induction de reponses immunitaires cellulaires aux antigenes du cancer de la prostate au moyen de compositions de peptides et d'acides nucleiques
WO2001075067A2 (fr) * 2000-03-31 2001-10-11 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
US20020081680A1 (en) * 2000-04-17 2002-06-27 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003070889A2 (fr) * 2002-02-19 2003-08-28 Idec Pharmaceuticals Corporation Genes specifiques de la prostate et leur utilisation dans la conception ou la therapie
WO2004016643A2 (fr) * 2002-08-16 2004-02-26 Yeda Research And Development Co. Ltd. Antigene specifique de tumeurs, peptides associes et utilisation de ceux-ci en tant que vaccins antitomoraux
WO2004053075A2 (fr) * 2002-12-05 2004-06-24 Diadexus, Inc. Compositions, variants d'epissage et procedes relatifs a des genes et des proteines specifiques du sein
WO2005033265A2 (fr) * 2003-04-25 2005-04-14 Epimmune Inc. Constructions multi-epitope optimisees et leurs utilisations
WO2006023598A2 (fr) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Peptides restreints par mhc classe ii derives d'antigenes specifiques a la prostate et leur utilisation dans des vaccins destines a traiter ou a prevenir le cancer de la prostate
EP2111867A1 (fr) * 2008-04-24 2009-10-28 Immatics Biotechnologies GmbH Nouvelles formules de peptides associées aux tumeurs à liaison aux molécules II ou I de classe d'antigène (HLA) de leucocyte humain pour vaccins
EP2119726A1 (fr) * 2008-05-14 2009-11-18 Immatics Biotechnologies GmbH Nouveaux peptides puissants de classe II-MHC dérivés de la survivine et neurocane
EP2172211A1 (fr) * 2008-10-01 2010-04-07 Immatics Biotechnologies GmbH Composition de peptide associé aux tumeurs et vaccin anti-cancer associé pour le traitement de glioblastome (GBM) et autres cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
DE602004019215D1 (de) 2004-10-02 2009-03-12 Immatics Biotechnologies Gmbh Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden
PT1806358E (pt) 2005-09-05 2010-05-28 Immatics Biotechnologies Gmbh Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045728A2 (fr) * 1999-12-21 2001-06-28 Epimmune Inc. Induction de reponses immunitaires cellulaires aux antigenes du cancer de la prostate au moyen de compositions de peptides et d'acides nucleiques
WO2001075067A2 (fr) * 2000-03-31 2001-10-11 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
US20020081680A1 (en) * 2000-04-17 2002-06-27 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003070889A2 (fr) * 2002-02-19 2003-08-28 Idec Pharmaceuticals Corporation Genes specifiques de la prostate et leur utilisation dans la conception ou la therapie
WO2004016643A2 (fr) * 2002-08-16 2004-02-26 Yeda Research And Development Co. Ltd. Antigene specifique de tumeurs, peptides associes et utilisation de ceux-ci en tant que vaccins antitomoraux
WO2004053075A2 (fr) * 2002-12-05 2004-06-24 Diadexus, Inc. Compositions, variants d'epissage et procedes relatifs a des genes et des proteines specifiques du sein
WO2005033265A2 (fr) * 2003-04-25 2005-04-14 Epimmune Inc. Constructions multi-epitope optimisees et leurs utilisations
WO2006023598A2 (fr) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Peptides restreints par mhc classe ii derives d'antigenes specifiques a la prostate et leur utilisation dans des vaccins destines a traiter ou a prevenir le cancer de la prostate
EP2111867A1 (fr) * 2008-04-24 2009-10-28 Immatics Biotechnologies GmbH Nouvelles formules de peptides associées aux tumeurs à liaison aux molécules II ou I de classe d'antigène (HLA) de leucocyte humain pour vaccins
EP2119726A1 (fr) * 2008-05-14 2009-11-18 Immatics Biotechnologies GmbH Nouveaux peptides puissants de classe II-MHC dérivés de la survivine et neurocane
EP2172211A1 (fr) * 2008-10-01 2010-04-07 Immatics Biotechnologies GmbH Composition de peptide associé aux tumeurs et vaccin anti-cancer associé pour le traitement de glioblastome (GBM) et autres cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIESSLING ET AL: "Advances in Specific Immunotherapy for Prostate Cancer", EUROPEAN UROLOGY, ELSEVIER BV, NL, vol. 53, no. 4, 26 November 2007 (2007-11-26), pages 694 - 708, XP022495956, ISSN: 0302-2838 *
QIN H ET AL: "Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 99, no. 1, 15 June 2005 (2005-06-15), pages 85 - 93, XP004891413, ISSN: 0165-2478, DOI: DOI:10.1016/J.IMLET.2005.01.006 *

Also Published As

Publication number Publication date
WO2012079878A2 (fr) 2012-06-21
NZ609916A (en) 2015-03-27
CA2821582A1 (fr) 2012-06-21
AU2011344652A1 (en) 2013-05-23
SG191154A1 (en) 2013-07-31
AU2011344652B2 (en) 2015-11-19
KR20130126671A (ko) 2013-11-20
CN103547283A (zh) 2014-01-29
JP6032853B2 (ja) 2016-11-30
MX2013006758A (es) 2013-08-01
JP2014502961A (ja) 2014-02-06

Similar Documents

Publication Publication Date Title
WO2011073215A3 (fr) Peptides se liant aux hla, dérivés de molécules antigéniques associées à la prostate, et leurs procédés d'utilisation
WO2012079878A3 (fr) Peptides se liant au hla dérivés de molécules antigéniques associées à la prostate et procédés d'utilisation associés
NZ603271A (en) Anti-erbb3 antibodies
CA2759013C (fr) Compositions d'immunotherapie de combinaison contre le cancer et methodes associees
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
WO2012177595A9 (fr) Compositions et méthodes pour la thérapie et le diagnostic du cancer
WO2012006634A3 (fr) Thérapie peptidique par antigène prostatique spécifique (psa)
AU2011338383A8 (en) Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
WO2011143656A3 (fr) Compositions et procédés d'identification de néoantigènes spécifiques à une tumeur
WO2012170776A3 (fr) Procédés de détermination du pronostic d'un patient pour la récurrence d'un cancer de la prostate et/ou déterminer une évolution de traitement pour un cancer de la prostate après une prostatectomie radicale
NZ631197A (en) Anti sez6 antibodies and methods of use
NZ707086A (en) Anti-cd40 antibodies and methods of use
SG194701A1 (en) Anti-cd40 antibodies and methods of use
SG10201903119QA (en) Polypeptide vaccine
NZ606195A (en) Methods and compositions for liver cancer therapy
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
MX2013010475A (es) Composiciones inmunoterapeuticas de levadura-brachyuri.
WO2013106834A3 (fr) Peptides wt-1 immunogènes et leurs procédés d'utilisation
WO2010003520A3 (fr) Immunothérapie antitumorale
WO2015200828A8 (fr) Conjugués pour immunothérapie
MX2011010955A (es) Terapia complementaria contra el cancer.
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
WO2012165815A3 (fr) Nano-véhicule issu d'un tissu tumoral et vaccin anti-cancer l'utilisant
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
MX2012013875A (es) Anticuerpos de union sparc en sangre periferica y usos de los mismos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11782613

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2011344652

Country of ref document: AU

Date of ref document: 20111114

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013543601

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2821582

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/006758

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: A201305361

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 20137018147

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2011782613

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011782613

Country of ref document: EP

Ref document number: 201300693

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 13993291

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013014771

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112013014771

Country of ref document: BR

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: 112013014771

Country of ref document: BR